新規利尿薬M17055の生体内動態 第3報  [`14´C]M17055反復静脈内投与時のラットにおける血中濃度,分布および排せつ

  • 中嶌 裕之
    持田製薬株式会社総合研究所 薬物動態研究室
  • 中西 猛
    持田製薬株式会社総合研究所 薬物動態研究室
  • 那波 弘康
    持田製薬株式会社総合研究所 薬物動態研究室
  • 井田 圭一
    持田製薬株式会社総合研究所 薬物動態研究室
  • 大澤 伸雄
    持田製薬株式会社総合研究所 薬物動態研究室

書誌事項

タイトル別名
  • Studies on the Metabolic Fate of M17055, a Novel Diuretic. (3): Plasma Concentration, Distribution and Excretion of Radioactivity in Male Rats after Repeated Daily Intravenous Administration of [14C]M17055.

この論文をさがす

説明

The plasma levels, tissue distribution and excretion of radioactivity were studied following repeated daily intravenous administration of [14C]M17055 to male rats at a dose of 0.3 mg/kg/day.<BR> 1. The plasma levels of radioactivity at 24 hours after each of 21 day-period of repeated administration to male rats were reached the steady state (6.90-8.87 ng eq./mL) by the 8th dosing. The calculated pharmacokinetic parameters were similar as those after the single administration.<BR> 2. Although the levels of radioactivity in all tissues at 24 hours after repeated administration to male rats rose according to the times of dosing, the rising rate was slow except for blood, lung, skin, digestive organs and their contents. At 1 hour after the 21st dosing, the radioactivity distributed highly to the liver and kidney as observed after the single administration. At 168 hours after the 21st dosing, the radioactivity tended to remain in highly perfused tissues, such as liver, kidney, spleen and lung. No tissue was identified in which the radioactivity retained for long period on the whole body autoradiograms.<BR> 3. Cumulative urinary and fecal excretions of radioactivity after 21 day repeated administration accounted for 58.17 and 37.35% of the total dose, respectively. The excretion rate in urine and feces well agreed to that after the single administration. The total excretion of radioactivity, including that present in the cage washing, accounted for 97.28% of the total dose.

収録刊行物

  • 薬物動態

    薬物動態 16 (4), 325-332, 2001

    日本薬物動態学会

被引用文献 (2)*注記

もっと見る

参考文献 (5)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ